An allele-dosage effect was found for the combination rs12945597 (TOP3A) and rs2532105 (BLM) for AML/MDS, bladder and breast cancer, where carriers with two variant alleles displayed the highest risks (Table 3A). This evidence concerns the gene BLM and breast carcinoma.